ES2177637T3 - Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico. - Google Patents

Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.

Info

Publication number
ES2177637T3
ES2177637T3 ES95912871T ES95912871T ES2177637T3 ES 2177637 T3 ES2177637 T3 ES 2177637T3 ES 95912871 T ES95912871 T ES 95912871T ES 95912871 T ES95912871 T ES 95912871T ES 2177637 T3 ES2177637 T3 ES 2177637T3
Authority
ES
Spain
Prior art keywords
nitric oxide
restenosis
releasing
treatment
medicines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912871T
Other languages
English (en)
Inventor
Larry K Keefer
Thomas C Hutsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Comedicus Inc
Original Assignee
US Department of Health and Human Services
Comedicus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Comedicus Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2177637T3 publication Critical patent/ES2177637T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONAN METODOS PARA MEJORAR, TRATAR Y PREVENIR LA RESTENOSIS ASI COMO TRASTORNOS ASOCIADOS. LOS METODOS IMPLICAN LA ADMINISTRACION DE OXIDO NITRICO MEDIANTE UN MEDIO DE LIBERACION DE OXIDO NITRICO CONSISTENTE EN UN MEJORANTE DE LA RESTENOSIS O UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE/PROFILACTICAMENTE DE UN POLIMERO AL QUE SE UNE UN GRUPO FUNCIONAL N{SUB,2}O{SUB,2} DE LIBERACION DE OXIDO NITRICO O UN COMPUESTO INTEGRADO POR UN GRUPO FUNCIONAL N{SUB,2}O{SUB,2} DE LIBERACION DE OXIDO NITRICO. TAMBIEN SE FACILITAN MEDIOS PARA LA LIBERACION DE OXIDO NITRICO QUE INCLUYEN LOS POLIMEROS DE LIBERACION DE OXIDO NITRICO MENCIONADOS O COMPUESTOS DE LOS MISMOS PARA UTILIZAR EN DICHOS METODOS. EL MEDIO DE LIBERACION PREFERIBLEMENTE ESTA CUBIERTO CON UN POLIMERO DE LIBERACION DE OXIDO NITRICO, QUE PUEDE SER BIODEGRADABLE, Y PERMITE LA LIBERACION CONTROLABLE Y PREDECIBLE DE NO A UN LUGAR DADO DE FORMA QUE SE PRODUZCA LA DOSIFICACION, PROFILACTICA, O MEJORA EFECTIVA.
ES95912871T 1994-03-17 1995-03-09 Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico. Expired - Lifetime ES2177637T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/214,372 US5650447A (en) 1992-08-24 1994-03-17 Nitric oxide-releasing polymers to treat restenosis and related disorders

Publications (1)

Publication Number Publication Date
ES2177637T3 true ES2177637T3 (es) 2002-12-16

Family

ID=22798839

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912871T Expired - Lifetime ES2177637T3 (es) 1994-03-17 1995-03-09 Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.

Country Status (11)

Country Link
US (1) US5650447A (es)
EP (1) EP0752866B1 (es)
JP (1) JPH10502905A (es)
AT (1) ATE218352T1 (es)
AU (1) AU698525B2 (es)
CA (1) CA2185457C (es)
DE (1) DE69526934T2 (es)
DK (1) DK0752866T3 (es)
ES (1) ES2177637T3 (es)
PT (1) PT752866E (es)
WO (1) WO1995024908A1 (es)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AU3986097A (en) * 1996-08-27 1998-03-19 University Of Akron, The Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US6372796B1 (en) * 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6645167B1 (en) 1999-05-21 2003-11-11 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an embolizing composition
WO2000071064A1 (en) * 1999-05-21 2000-11-30 Micro Therapeutics, Inc. Methods for delivering in vivo uniform dispersed embolic compositions of high viscosity
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
EP1207811A4 (en) * 1999-08-04 2007-03-07 Bard Inc C R STAIN OXIDE RELEASE MEDICAL ARTICLES
US6569082B1 (en) 1999-08-10 2003-05-27 Origin Medsystems, Inc. Apparatus and methods for cardiac restraint
US20040102804A1 (en) * 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
US7398781B1 (en) * 1999-08-10 2008-07-15 Maquet Cardiovascular, Llc Method for subxiphoid endoscopic access
US7526342B2 (en) * 1999-08-10 2009-04-28 Maquet Cardiovascular Llc Apparatus for endoscopic cardiac mapping and lead placement
US20030187461A1 (en) * 1999-08-10 2003-10-02 Chin Albert K. Releasable guide and method for endoscopic cardiac lead placement
US7597698B2 (en) * 1999-08-10 2009-10-06 Maquet Cardiovascular Llc Apparatus and method for endoscopic encirclement of pulmonary veins for epicardial ablation
US7288096B2 (en) 2003-01-17 2007-10-30 Origin Medsystems, Inc. Apparatus for placement of cardiac defibrillator and pacer
US20060287574A1 (en) * 1999-08-25 2006-12-21 Chin Albert K Longitudinal dilator
US6660260B1 (en) 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
CA2396628A1 (en) * 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
DE60136366D1 (de) * 2000-08-11 2008-12-11 David R Whitlock Ammoniak-oxidierende bakterien enthaltende zusammensetzungen zur steigerung der stickoxidproduktion, stickoxid-vorläufer und verfahren zu deren verwendung
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
US20050043506A1 (en) * 2000-09-27 2005-02-24 Michigan Biotechnology Institute Polyamide materials based on unsaturated carboxylic acids and amines
JP2004515271A (ja) * 2000-10-11 2004-05-27 マイクロ・セラピューティクス・インコーポレーテッド 動脈瘤の治療方法
EP2292190B1 (en) 2000-10-16 2017-11-08 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7049308B2 (en) * 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6565601B2 (en) 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
DE60117857D1 (de) * 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE60233140D1 (de) 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
EP1436018A1 (en) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
EP1472021A4 (en) * 2002-01-11 2008-04-16 David R Whitlock AMMONIAX OXIDIZING BACTERIA CONTAINING COMPOSITIONS AND USER METHOD THEREFOR
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
TW200307734A (en) 2002-03-20 2003-12-16 Michigan Biotech Inst Conductive polymer-based material
CA2480033C (en) * 2002-03-21 2011-05-10 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
EP1507526A2 (en) * 2002-05-07 2005-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
EP1545798A4 (en) * 2002-08-02 2006-06-14 Us Gov Health & Human Serv NETWORKED NITROGEN OXIDE RELEASING POLYAMINE-COATED SUBSTRATES, THESE COMPOSITIONS AND MANUFACTURING PROCESSES DAF R
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
EP1624953B1 (en) * 2003-04-23 2018-12-19 The University of Akron Sequestered reactive materials
BRPI0412273B1 (pt) * 2003-07-03 2019-09-24 The University Court Of The University Of St. Andrews Preparação farmacêutica, uso de um material de zeólito, artigo médico, produto cosmético e/ou de higiene pessoal, e, método de liberação de óxido nítrico
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2005067815A1 (en) * 2004-01-05 2005-07-28 Zygo Corporation Stage alignment in lithography tools
US8298563B2 (en) * 2004-01-22 2012-10-30 The University Of Akron Polymer no donor predrug nanofiber coating for medical devices and therapy
AU2005207037A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US20050165452A1 (en) * 2004-01-28 2005-07-28 Medtronic, Inc. Antithrombogenic medical device
CA2555591C (en) * 2004-02-09 2011-01-04 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
EP1746882A4 (en) * 2004-03-31 2010-08-25 Nitromed Inc METHODS OF TREATING BLOOD DISORDERS USING NITRIC OXIDE DONOR COMPOUNDS
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
CA2581939C (en) 2004-09-27 2013-01-08 Joseph A. Hrabie Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US20080300292A1 (en) * 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1690532A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for gastric treatment and manufacturing process for the same
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
EP2119459A1 (en) * 2005-02-11 2009-11-18 NOLabs AB Treatment of neuropathy involving nitric oxide
US20090012057A1 (en) * 2005-02-28 2009-01-08 Nitromed, Inc. Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
WO2006110601A2 (en) * 2005-04-07 2006-10-19 Nitromed, Inc. The genetic risk assessment in heart failure: impact of the genetic variation of nos3
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
EP3556401A1 (en) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
JP2008544820A (ja) * 2005-06-30 2008-12-11 エムシー３， インコーポレイテッド 医療デバイスのための一酸化窒素コーティング
WO2007005758A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Methods , compositions and devices for promoting angiogenesis
JP2009500083A (ja) * 2005-06-30 2009-01-08 エムシー３， インコーポレイテッド 検体センサーおよびその中で使用するための組成物
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
WO2007041680A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
WO2007053292A2 (en) * 2005-10-31 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CN101378792A (zh) * 2005-12-02 2009-03-04 密执安大学评议会 聚合物组合物、涂层和装置及其制备和使用方法
EP1968615A4 (en) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc POLYMERS RELEASING NITRIC OXIDE
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007126609A1 (en) 2006-03-29 2007-11-08 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) * 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
WO2009064861A2 (en) * 2007-11-13 2009-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof
US20090170933A1 (en) * 2007-12-26 2009-07-02 Cook Incorporated Method for removing a medical device from a spasmodic constriction in a bodily passageway
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
CA2717867C (en) 2008-03-07 2017-05-30 Paul J. Shami Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
CA3186201A1 (en) * 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
US20110301299A1 (en) 2010-06-08 2011-12-08 Medtronic Vascular, Inc. Medical Devices and Polymers Therefor Having PTFE Surfaces Modified With Nitric Oxide-Releasing Polymers
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
CA2835320A1 (en) 2011-05-09 2012-11-15 Topical Therapeutic Agent (Tta) Ltd. Nitric oxide-sequestering topical formulations
CA3207619A1 (en) 2014-04-15 2015-10-22 Aobiome Llc Ammonia-oxidizing nitrosomonas eutropha strain d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
US10221257B2 (en) * 2014-08-14 2019-03-05 Rohm And Haas Company Polymer with releasable gas
EP3253485B1 (en) 2015-02-03 2021-12-15 University Court of The University of St Andrews No containing compositions
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2021515083A (ja) 2018-03-06 2021-06-17 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法
US11421044B2 (en) 2018-12-28 2022-08-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
WO2023081681A1 (en) * 2021-11-03 2023-05-11 Baxter International Inc. Nitric oxide donors for use in surgical recovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL151996B (nl) * 1971-04-15 1977-01-17 Snam Progetti Werkwijze voor de bereiding van gemodificeerde polymeren.
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5185376A (en) * 1991-09-24 1993-02-09 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
US5219710A (en) * 1991-11-25 1993-06-15 Allied-Signal Inc. Polymeric nitrones having a styrene-derived backbone chain

Also Published As

Publication number Publication date
WO1995024908A1 (en) 1995-09-21
US5650447A (en) 1997-07-22
CA2185457C (en) 2004-05-25
PT752866E (pt) 2002-11-29
AU1988995A (en) 1995-10-03
EP0752866A1 (en) 1997-01-15
ATE218352T1 (de) 2002-06-15
EP0752866B1 (en) 2002-06-05
DE69526934D1 (de) 2002-07-11
DK0752866T3 (da) 2002-09-16
AU698525B2 (en) 1998-10-29
CA2185457A1 (en) 1995-09-21
DE69526934T2 (de) 2003-01-02
JPH10502905A (ja) 1998-03-17

Similar Documents

Publication Publication Date Title
ES2177637T3 (es) Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.
BR9206631A (pt) Sistema de maior penetração na pele para melhor administração tópica de medicamentos
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
GEP20043297B (en) Bicyclic Amino Acids as Pharmaceutical Agents
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
CY1107389T1 (el) Σελεκοξιμπη σε μορφη στερεης καταστασης με ενισχυμενη βιοδιαθεσιμοτητα
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
DE60141567D1 (de) Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
ES2194392T3 (es) Derivados alfa-aminoamidicos utiles como agentes analgesicos.
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
BR0316279A (pt) Compostos orgânicos
FI942922A0 (fi) Asetyylisalisyylihappoa sisältävä ihon läpi tapahtuva antojärjestelmä antitromboottiseen terapiaan ja syövän ehkäisyyn
PT1003477E (pt) Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
BR9709316A (pt) Composição farmacêutica para administração tópica no tratamento da vaginite
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BR0213634A (pt) Sistema de liberação de droga com ação retardada para um agente antiespasmódico
ATE247965T1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
FR2801217B1 (fr) Association de riluzole et de gabapentine et son utilisation comme medicament
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände